Incyte Dividenden en inkoop
Dividend criteriumcontroles 0/6
Incyte heeft geen dividenduitkeringen gedaan.
Belangrijke informatie
n/a
Dividendrendement
-1.2%
Terugkoop Rendement
| Totaal aandeelhoudersrendement | -1.2% |
| Toekomstig dividendrendement | 0% |
| Dividendgroei | n/a |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | n/a |
| Uitbetalingsratio | n/a |
Recente updates van dividend en inkoop
Geen updates
Recent updates
Narratiefupdate • Sep 08
INCY: Future Returns Will Hinge On KRAS Data And Post Jakafi Execution
Analysts have nudged their average price target higher for Incyte, with fair value rising from about $124.96 to $127.74. They cite broadly supportive Q2 research updates that highlight solid commercial execution, a fuller late stage pipeline and a series of higher individual targets that now cluster between roughly $104 and $152.Seeking Alpha • Sep 08
Incyte: Solid Strategies For Continued Growth, But A Possible Pullback Looms
Summary Incyte Corporation outperformed, rising 34% versus the S&P 500's 15% since March 2026. Q2 2026 results were robust: revenue was up 38% to $1.67B, and EPS was up 97% to $3.09, both beating estimates. Incyte has been doing a great job of increasing key product sales while developing its pipeline. Technical indicators suggest INCY is due for a pullback despite recent operational strength. Read the full article on Seeking Alpha
Narratiefupdate • Aug 25
INCY: Post Jakafi Cliff Risk Will Limit Vega Bleeding Franchise Upside
Analysts have lifted their blended price target and fair value estimate for Incyte, with the model now pointing to about $92.65 per share. This move is supported by a wave of higher Street targets following solid Q2 results, increased confidence in late stage assets such as VGA039 and '734, and an updated outlook that assumes a richer future P/E multiple alongside slightly higher discounting and a more resilient profit margin profile, despite more cautious revenue growth assumptions.Narratiefupdate • Aug 11
INCY: Future Returns Will Depend On Post Jakafi Pipeline And Execution
The analyst price target for Incyte has been reset higher from $114.55 to $124.96 as analysts factor in a series of post Q2 target hikes that highlight solid commercial execution, clearer post Jakafi plans, and a portfolio that some see as increasingly supported by late-stage assets and potential upcoming catalysts. Analyst Commentary Recent research views on Incyte show a mix of optimism around execution and pipeline progress, alongside ongoing questions about how the company handles the eventual Jakafi loss of exclusivity and competition in key disease areas.Analyse-artikel • Jul 31
Earnings Beat: Incyte Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
A week ago, Incyte Corporation ( NASDAQ:INCY ) came out with a strong set of quarterly numbers that could potentially...Narratiefupdate • Jul 28
INCY: Future Returns Will Hinge On Replacing Jakafi And Advancing Hematology Pipeline
Analysts have lifted the Incyte fair value estimate from $108.50 to about $114.55, reflecting modestly higher assumptions for revenue growth, profit margins and future P/E, along with a slightly lower discount rate, based on a recent series of upward price target revisions across the Street. Analyst Commentary Recent research on Incyte shows a mix of optimism and caution.Narratiefupdate • Jul 14
INCY: Post Jakafi Cliff Will Outweigh Vega Von Willebrand Opportunity
Analysts have lifted the fair value estimate for Incyte stock from $79.38 to $82.16, citing refreshed revenue growth assumptions, updated margins, and a higher future P/E multiple supported by recent price target increases from several research firms following the Vega Therapeutics acquisition and evolving views on the post Jakafi portfolio. Analyst Commentary Recent research on Incyte reflects a mix of optimism around pipeline additions like Vega Therapeutics and continued caution around execution and life after Jakafi.Narratiefupdate • Jun 30
INCY: Jakafi 2028 Cliff Will Challenge Vega Von Willebrand Acquisition
Incyte's analyst price targets have moved higher, with recent raises into the $94 to $113 range as analysts factor in the Vega Therapeutics acquisition, updated expectations for von Willebrand disease assets, and management's efforts to prepare for Jakafi's eventual loss of exclusivity. Analyst Commentary Recent research coverage on Incyte highlights a mixed backdrop, with several firms lifting price targets into the mid to high US$90s and low US$100s while keeping ratings largely in the middle of the road.Analyse-artikel • Jun 17
Incyte (INCY) Stock Could Be 8.1% Undervalued After FDA Priority Review And Trial Results
Recent interest in Incyte (INCY) stock is closely tied to fresh clinical and regulatory milestones, including pivotal data for zilurgisertib in fibrodysplasia ossificans progressiva and Phase 3 results for tafasitamab plus lenalidomide with R-CHOP. See our latest analysis for Incyte. Incyte stock has cooled slightly in the very short term, with a 1-day share price return of 2.19% and a 7-day share price return of 5.35%. However, the 1-year total shareholder return of 46.11% and 3-year total...
Narratiefupdate • Jun 16
INCY: Hematology Pipeline And Vega Acquisition Will Cushion Upcoming Patent Cliff
Analysts have nudged the fair value estimate for Incyte up by $5 to $140, citing the Vega Therapeutics acquisition and its Phase 3-ready von Willebrand disease asset as a potential long-term offset to Jakafi loss of exclusivity, while also modestly adjusting assumptions for revenue growth, profit margins, discount rate, and future P/E. Analyst Commentary Recent research on Incyte highlights a split view.Narratiefupdate • Jun 02
INCY: Jakafi 2028 Cliff Will Expose Uncertain mutCALR Pipeline Transition
Analysts have nudged their fair value estimate for Incyte higher to about $74.53 from $72.33, reflecting updated views on long term revenue pressure after Jakafi’s expected loss of exclusivity, incremental support from early stage assets like INCA033989, and mixed sentiment on longer term growth that has also led to a slightly higher assumed P/E multiple. Analyst Commentary Analyst views on Incyte remain mixed, with the core debate centered on how the company will handle the patent cliff tied to Jakafi and whether early stage assets like INCA033989 can eventually support the current valuation.Analyse-artikel • May 10
Impressive Earnings May Not Tell The Whole Story For Incyte (NASDAQ:INCY)
Incyte Corporation ( NASDAQ:INCY ) announced strong profits, but the stock was stagnant. We did some digging, and we...Narratiefupdate • May 03
INCY: Future Returns Will Depend On Managing Patent Cliff And Pipeline Execution
Incyte's updated analyst price target has moved from $100.10 to $108.50, reflecting how analysts are weighing a series of recent target hikes from firms such as Oppenheimer, BofA, RBC, Barclays, Morgan Stanley, Piper Sandler and H.C. Wainwright, against more cautious views from UBS and Jefferies focused on patent and long term growth uncertainties. Analyst Commentary Recent research highlights a clear split in how analysts view Incyte, with several firms lifting price targets or initiating with a positive stance, while others focus on patent risk and long term growth questions.Narratiefupdate • Apr 18
INCY: Jakafi 2028 Patent Cliff Will Pressure Reliance On Long Dated Pipeline
The analyst price target for Incyte has shifted to reflect a modest fair value increase of about $2, as analysts weigh patent cliff concerns around Jakafi in 2028 against longer term pipeline opportunities and a higher assumed future P/E multiple. Analyst Commentary Recent research has highlighted a split view on Incyte, with some firms lifting price targets while others have taken a more cautious stance.Narratiefupdate • Apr 04
INCY: Late Stage Pipeline And 2026 Readouts Will Offset Patent Cliff Risk
Analysts have modestly adjusted their price targets on Incyte, with recent cuts of up to $10 alongside several incremental increases. This reflects a balance between concerns around Jakafi's 2028 patent cliff and confidence in longer term revenue drivers that are considered harder to underwrite today.Narratiefupdate • Mar 21
INCY: Late Stage Pipeline And 2026 Milestones Will Offset Patent Cliff Risk
Analysts' price targets for Incyte have shifted, with one firm cutting its view from $120 to $94 on patent cliff concerns, while others have nudged targets higher into the $90 to $128 range. This reflects a balance between Jakafi loss of exclusivity risk and longer term pipeline potential.Narratiefupdate • Mar 07
INCY: Late Stage Pipeline Progress And 2026 Readouts Will Reshape Earnings Power
Incyte's updated analyst price target has nudged higher, with several firms lifting their views into a roughly $117 to $128 range as analysts highlight a clearer revenue roadmap, upcoming Phase 3 catalysts, and a more constructive sector backdrop, despite at least one downgrade on near term catalysts. Analyst Commentary Recent Street research around Incyte has tilted constructive, with several bullish analysts revisiting their models and lifting price targets as they get more confidence in the company’s roadmap and execution plans.Narratiefupdate • Feb 21
INCY: Late Stage Pipeline Execution Will Reshape Earnings Power Beyond Jakafi
The analyst fair value estimate for Incyte has been raised by $6 to $135. This change reflects recent price target increases across several firms as analysts point to a fuller pipeline, higher assumed revenue growth, a higher future P/E multiple, and offsetting adjustments to discount rate and profit margin assumptions.Narratiefupdate • Feb 06
INCY: Late Stage Pipeline Reliance Will Face Pressure As Near Term Catalysts Remain Scarce
Analysts have lifted their price targets on Incyte by as much as US$27, citing a fuller late stage pipeline, new coverage with bullish views, and updated assumptions around discount rates, revenue growth, profit margins, and forward P/E that support a higher valuation range. Analyst Commentary Recent research on Incyte has tilted more constructive on potential upside, but there are also clear points of caution that investors should keep in mind when thinking about valuation and execution risk.Narratiefupdate • Jan 23
INCY: Late Stage Pipeline Execution Will Face Scrutiny As Near Term Catalysts Thin
Narrative Update: Incyte (INCY) The updated analyst price target for Incyte moves from $60 to $70, reflecting analysts' incorporation of higher projected profit margins, a lower future P/E, and recent price target raises that highlight a fuller late stage pipeline and upcoming clinical readouts, even as some research points to fewer near term catalysts. Analyst Commentary Recent Street commentary on Incyte mixes higher price targets with tempered expectations around the pace and reliability of execution.Narratiefupdate • Jan 09
INCY: Pipeline Progress And Policy Tailwinds Will Reshape Earnings Power
Analysts have lifted their fair value estimate for Incyte to $129 from $92, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E following recent Street research, including the higher $90 price target cited by Goldman Sachs. Analyst Commentary Recent Street research has added a more constructive tone around Incyte, with bullish analysts pointing to updated assumptions on risk, growth, and profitability to support higher valuation frameworks.Narratiefupdate • Dec 25
INCY: Future Returns Will Hinge On Executing High-Expectation Pipeline Under New Leadership
Analysts have nudged their price target on Incyte slightly higher, to $82 from $81. This reflects a modestly improved fair value estimate even as they caution that the recent share rally has largely priced in high expectations for key pipeline assets and new management.Narratiefupdate • Dec 11
INCY: Future Returns Will Depend On Delivering High-Risk Hematology Pipeline Milestones
Analysts have nudged their fair value estimate for Incyte higher, lifting the implied price target by about $4 per share to roughly $100. They are balancing moderate upward revisions to growth assumptions and valuation multiples against a view that recent gains already reflect high expectations for key pipeline assets and Opzelura expansion.Narratiefupdate • Nov 27
INCY: Share Momentum Will Slow As R&D Execution Risks Remain Elevated
Incyte's analyst price target has increased modestly to $95.57 from $93.82. Analysts cite continued pipeline momentum, recent regulatory approvals, and new leadership as key drivers supporting higher valuation expectations.Narratiefupdate • Nov 12
INCY: Share Momentum Will Stall As Execution Risks Come Into Focus
Incyte's analyst price target has increased from $86.86 to $93.82, as analysts cite improving profit margins, strong product pipeline updates, and enhanced growth visibility following recent regulatory and clinical developments. Analyst Commentary Recent analyst research on Incyte reflects a range of perspectives on the company's valuation, growth potential, and commercial execution.Analyse-artikel • Oct 31
Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts
Incyte Corporation ( NASDAQ:INCY ) defied analyst predictions to release its quarterly results, which were ahead of...Narratiefupdate • Oct 29
Upcoming Clinical Data And New Management Will Shape Future Performance
Incyte's analyst fair value price target has been raised by nearly $2 to approximately $87, as analysts point to recent clinical updates and pipeline progress strengthening the company's growth outlook. Analyst Commentary Recent Street research on Incyte reflects a mix of optimism regarding the company's growth drivers and caution about valuation and future risks.Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van INCY in het verleden stabiel is geweest.
Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van INCY zijn gestegen.
Dividendrendement versus markt
| Incyte Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (INCY) | n/a |
| Markt onderkant 25% (US) | 1.4% |
| Markt Top 25% (US) | 4.1% |
| Gemiddelde industrie (Biotechs) | 2.1% |
| Analist prognose (INCY) (tot 3 jaar) | 0% |
Opmerkelijk dividend: Het dividendrendement van INCY kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Hoog dividend: Het dividendrendement van INCY kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Winstuitkering aan aandeelhouders
Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio INCY te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat INCY geen uitbetalingen heeft gerapporteerd.
Ontdek bedrijven met een sterk dividend
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/09 14:10 |
| Aandelenkoers aan het einde van de dag | 2026/09/09 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Incyte Corporation wordt gevolgd door 47 analisten. 22 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Thomas Russo | Baird |
| Peter Lawson | Barclays |